HUE054055T2 - Opoid receptor ligandumok és eljárás azok alkalmazására és elõállítására - Google Patents

Opoid receptor ligandumok és eljárás azok alkalmazására és elõállítására

Info

Publication number
HUE054055T2
HUE054055T2 HUE17173483A HUE17173483A HUE054055T2 HU E054055 T2 HUE054055 T2 HU E054055T2 HU E17173483 A HUE17173483 A HU E17173483A HU E17173483 A HUE17173483 A HU E17173483A HU E054055 T2 HUE054055 T2 HU E054055T2
Authority
HU
Hungary
Prior art keywords
preparation
methods
receptor ligands
opoid receptor
opoid
Prior art date
Application number
HUE17173483A
Other languages
English (en)
Hungarian (hu)
Inventor
Dennis Yamashita
Dimitar Gotchev
Philip Pitis
Xiao-Tao Chen
Guodong Liu
Catherine C K Yuan
Original Assignee
Trevena Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46877853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE054055(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Trevena Inc filed Critical Trevena Inc
Publication of HUE054055T2 publication Critical patent/HUE054055T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE17173483A 2011-03-23 2012-03-23 Opoid receptor ligandumok és eljárás azok alkalmazására és elõállítására HUE054055T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161466809P 2011-03-23 2011-03-23
US201261596808P 2012-02-09 2012-02-09

Publications (1)

Publication Number Publication Date
HUE054055T2 true HUE054055T2 (hu) 2021-08-30

Family

ID=46877853

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE17173483A HUE054055T2 (hu) 2011-03-23 2012-03-23 Opoid receptor ligandumok és eljárás azok alkalmazására és elõállítására
HUE12760456A HUE032948T2 (en) 2011-03-23 2012-03-23 Opioid receptor ligands and methods of using and making same

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE12760456A HUE032948T2 (en) 2011-03-23 2012-03-23 Opioid receptor ligands and methods of using and making same

Country Status (22)

Country Link
US (8) US8835488B2 (enExample)
EP (3) EP3290415B1 (enExample)
JP (6) JP5912169B2 (enExample)
KR (3) KR101991326B1 (enExample)
CN (1) CN103702561B (enExample)
AU (2) AU2012230761B2 (enExample)
CA (1) CA2830742C (enExample)
CY (1) CY1119057T1 (enExample)
DK (2) DK3290415T3 (enExample)
EA (1) EA025456B1 (enExample)
ES (2) ES2632009T3 (enExample)
HR (1) HRP20171021T1 (enExample)
HU (2) HUE054055T2 (enExample)
IL (4) IL228506A (enExample)
LT (1) LT2688403T (enExample)
ME (1) ME02754B (enExample)
PL (2) PL3290415T3 (enExample)
PT (2) PT2688403T (enExample)
RS (1) RS56111B1 (enExample)
SI (1) SI2688403T1 (enExample)
SM (1) SMT201700325T1 (enExample)
WO (1) WO2012129495A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE054055T2 (hu) * 2011-03-23 2021-08-30 Trevena Inc Opoid receptor ligandumok és eljárás azok alkalmazására és elõállítására
US9540343B2 (en) 2011-07-06 2017-01-10 Gilead Sciences, Inc. Compounds for the treatment of HIV
TWI706945B (zh) 2013-03-01 2020-10-11 美商基利科學股份有限公司 供治療反轉錄病毒科病毒感染之治療性化合物
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
AU2016323992B2 (en) 2015-09-16 2021-05-06 Eli Lilly And Company Farnesoid X receptor agonists and uses thereof
EP3350158A4 (en) 2015-09-16 2019-05-08 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2017049177A1 (en) 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
CN106588899B (zh) * 2015-10-15 2019-11-15 江苏恒瑞医药股份有限公司 吡啶基取代的6-氧杂螺[4.5]癸烷类衍生物、其制备方法及其在医药上的应用
EP3354649B1 (en) * 2015-10-15 2019-12-04 Jiangsu Hengrui Medicine Co., Ltd. Oxa spiro derivative, preparation method therefor, and applications thereof in medicines
KR20180093930A (ko) * 2015-12-14 2018-08-22 트레베나, 인코포레이티드. 통각과민증을 치료하는 방법
WO2017105881A1 (en) * 2015-12-15 2017-06-22 NeuForm Pharmaceuticals, Inc. Deuterated compounds for treating pain
CA3008637A1 (en) * 2015-12-17 2017-06-22 Trevena, Inc. Combinations of opioid receptor ligands and cytochrome p450 inhibitors
CN107098876B (zh) * 2016-02-23 2021-04-06 江苏恒瑞医药股份有限公司 苯基丙酰胺类衍生物、其制备方法及其在医药上的应用
JP6889186B2 (ja) * 2016-07-01 2021-06-18 ノイフォルム・ファーマシューティカルズ・インコーポレイテッドＮｅｕｆｏｒｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 疼痛を治療するための重水素化合物
BR112018071678B1 (pt) 2016-08-19 2021-01-26 Gilead Sciences, Inc. compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infecção por vírus hiv e suas composições farmacêuticas
WO2018108319A1 (en) * 2016-12-16 2018-06-21 Laboratorios Del Dr. Esteve, S.A. Tetrahydropyran and tetrahydrothiopyran amide derivatives having multimodal activity against pain
AU2018221705B2 (en) * 2017-02-17 2022-10-27 Trevena, Inc. 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
US11702408B2 (en) 2017-02-17 2023-07-18 Trevena, Inc. 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
LT3609888T (lt) 2017-03-15 2025-11-10 Farnezoidinio x receptoriaus agonistai ir jų panaudojimas
CA3055990A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
BR112019020691A2 (pt) 2017-04-14 2020-05-12 Jiangsu Hengrui Medicine Co., Ltd. Composição farmacêutica contendo agonista do mor e agonista do kor, e usos da mesma
CN108727347B (zh) * 2017-04-14 2020-06-16 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的晶型及其制备方法
ES2828636T3 (es) * 2017-04-14 2021-05-27 Jiangsu Hengrui Medicine Co Sal agonista de receptores opioides (MOR), forma cristalina I de la sal de fumarato de la misma y método de preparación de las mismas
CN115124520A (zh) * 2017-07-04 2022-09-30 四川海思科制药有限公司 阿片受体激动剂及其应用
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
EP3686198B1 (en) * 2017-09-18 2022-12-14 Shanghai Synergy Pharmaceutical Sciences Co., Ltd Mu-opioid receptor agonist and preparation method therefor and use thereof in field of medicine
BR112020005858A2 (pt) * 2017-09-28 2020-09-29 Jiangsu Hengrui Medicine Co., Ltd. compostos derivados oxaspirocíclicos e intermediários do mesmo, métodos de preparação e uso dos referidos compostos
WO2019072235A1 (zh) 2017-10-13 2019-04-18 南京明德新药研发股份有限公司 2,6-二氧杂螺[4,5]癸烷类衍生物、其制备方法及其在医药上的应用
EP3714882A4 (en) 2017-12-06 2021-09-01 Jiangsu Hengrui Medicine Co., Ltd. USE OF A KOR AGONIST IN COMBINATION WITH A MOR AGONIST IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF PAIN
US10604489B2 (en) 2018-02-05 2020-03-31 Alkermes, Inc. Compounds for the treatment of pain
PL3752495T3 (pl) 2018-02-15 2024-01-15 Gilead Sciences, Inc. Pochodne pirydynowe i ich zastosowanie do leczenia infekcji hiv
TWI823164B (zh) 2018-02-16 2023-11-21 美商基利科學股份有限公司 用於製備有療效化合物之方法及中間物
WO2019205983A1 (zh) * 2018-04-28 2019-10-31 四川科伦博泰生物医药股份有限公司 氧杂螺环类化合物及其制备方法和用途
CN111163778B (zh) * 2018-05-14 2023-01-24 江苏恒瑞医药股份有限公司 一种mor受体激动剂药物组合物
CA3216031A1 (en) 2018-07-16 2020-01-23 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
CN113056271B (zh) 2018-09-18 2024-10-29 奥加诺沃公司 法尼醇x受体激动剂及其用途
CN112638906B (zh) * 2018-10-12 2022-05-27 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
CN112638907B (zh) * 2018-10-12 2022-04-12 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
WO2020147848A1 (zh) * 2019-01-17 2020-07-23 上海海雁医药科技有限公司 三环取代的氧杂螺环衍生物、其制法与医药上的用途
CN111662284B (zh) * 2019-03-06 2021-08-10 上海海雁医药科技有限公司 双杂环取代的氧杂螺环衍生物、其制法与医药上的用途
TWI854067B (zh) 2019-11-26 2024-09-01 美商基利科學股份有限公司 預防hiv之蛋白殼抑制劑
EP4092032A4 (en) * 2020-01-17 2024-02-28 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. OPTICALLY PURE OXASPIRO-SUBSTITUTED PYRROLOPYRAZOLE DERIVATIVE, PROCESS THEREOF AND PHARMACEUTICAL USE THEREOF
KR102847070B1 (ko) 2020-01-17 2025-08-14 상하이 하이옌 파마슈티컬 테크놀로지 컴퍼니, 리미티드 아자비시클릭 치환된 옥사스피로 유도체, 이의 제조 방법 및 의학적 용도
CN113214264B (zh) * 2020-01-21 2022-08-09 上海海雁医药科技有限公司 二氢吡咯并五元杂芳基取代的氧杂螺环衍生物、其制法与医药上的用途
TWI872230B (zh) 2020-03-18 2025-02-11 美商奧加諾沃公司 法尼醇x受體促效劑之調配物
TW202502766A (zh) 2020-06-25 2025-01-16 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
WO2022033380A1 (zh) * 2020-08-10 2022-02-17 成都苑东生物制药股份有限公司 一种mor受体激动剂化合物、制备方法及其用途
CN112694485B (zh) * 2020-09-10 2023-04-07 四川海品信医药科技有限公司 一种阿片受体激动剂噻吩类化合物及其制备方法
WO2022143715A1 (zh) 2020-12-29 2022-07-07 上海海雁医药科技有限公司 氧杂螺环取代的吡咯并吡唑衍生物及其中间体和制备方法
AU2022312049B2 (en) 2021-07-13 2025-04-17 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Pharmaceutically acceptable salt of mor receptor agonist, and polymorph thereof and use thereof
CN115677675B (zh) * 2021-07-21 2025-09-12 成都苑东生物制药股份有限公司 一种6-氧杂螺[4,5]癸烷类化合物的盐、制备方法及用途
TW202321258A (zh) * 2021-08-02 2023-06-01 大陸商上海樞境生物科技有限公司 氧雜螺環類衍生物、製備方法及其用途
CN116075505A (zh) * 2021-08-31 2023-05-05 天地恒一制药股份有限公司 阿片受体激动剂及其制备方法和用途
EP4440701A1 (en) 2021-12-03 2024-10-09 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
TW202342448A (zh) 2021-12-03 2023-11-01 美商基利科學股份有限公司 用於ｈｉｖ病毒感染之治療性化合物
EP4440702B1 (en) 2021-12-03 2025-05-21 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
CN116041336B (zh) * 2022-01-21 2024-07-09 成都硕德药业有限公司 一种6-氧杂螺[4,5]癸烷类化合物的新晶型、用途及其制备方法
CN116589451B (zh) * 2022-02-11 2024-07-09 成都硕德药业有限公司 一种6-氧杂螺[4,5]癸烷类化合物的新晶型、用途及其制备方法
CN118638109B (zh) * 2024-04-30 2025-10-28 中山大学 一种阿片类药物-奥赛利定的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5825980B2 (ja) 1976-02-12 1983-05-31 ヤマサ醤油株式会社 サイクリックヌクレオチドの定量法
US4602035A (en) * 1983-12-07 1986-07-22 Hoechst-Roussel Pharmaceuticals Inc. Antidepressant (3-aryl-2,3-dihydrobenzofuran-3-yl)alkylamines
US5223530A (en) 1990-07-31 1993-06-29 Sri, International Arylcycloalkanepolyalkylamine ligands
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
AU3192295A (en) * 1994-08-11 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Substituted amine derivative and medicinal composition containing the same
JPH11507670A (ja) 1995-06-12 1999-07-06 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ−２インヒビターと５−リポキシゲナーゼインヒビターの組合せによる炎症と炎症関連疾患の治療
US6071918A (en) 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
GB0130261D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Lactams as tachykinin antagonists
TW200307539A (en) * 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
ES2305491T3 (es) * 2002-09-19 2008-11-01 Eli Lilly And Company Eteres de diarilo como antagonistas de receptores de opioides.
CN101921279A (zh) * 2003-10-01 2010-12-22 阿得罗公司 螺环杂环衍生物及其应用方法
WO2007041341A2 (en) * 2005-09-29 2007-04-12 The Trustees Of Columbia University In The City Of New York Identification of anti-cancer compounds and compounds for treating huntington's disease and methods of treatment thereof
US20070203224A1 (en) * 2006-01-09 2007-08-30 University Of Southern California Small-molecules for treating cancer and abnormal cell proliferation disorders
US7645767B2 (en) 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
EP2094692B1 (en) * 2006-11-01 2012-11-28 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof
WO2008057857A1 (en) * 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
WO2009018169A1 (en) 2007-07-27 2009-02-05 Auspex Pharmaceuticals, Inc. Substituted cyclohexanols
CL2009000731A1 (es) * 2008-03-27 2009-05-15 Gruenenthal Gmbh Compuestos derivados de ciclohexano espirociclicos sustituidos, composicion farmaceutica que contiene a dicho compuesto y su uso como moduladores del receptor de opioides µ y el receptor orl-1 para tratar el dolor, ansiedad, depresion, epilepsia, alzheimer, abuso de alcohol, hipertension, anorexia, obesidad y diarrea.
FR2939136B1 (fr) * 2008-12-02 2010-12-03 Galderma Res & Dev Nouveaux composes 4-(heterocycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
FR2967672B1 (fr) * 2010-11-22 2012-12-28 Sanofi Aventis Derives de nitrobenzothiazoles, leur preparation et leurs applications therapeutiques
HUE054055T2 (hu) * 2011-03-23 2021-08-30 Trevena Inc Opoid receptor ligandumok és eljárás azok alkalmazására és elõállítására
KR20180093930A (ko) 2015-12-14 2018-08-22 트레베나, 인코포레이티드. 통각과민증을 치료하는 방법

Also Published As

Publication number Publication date
AU2017200745A1 (en) 2017-02-23
KR101991327B1 (ko) 2019-06-20
KR20190072665A (ko) 2019-06-25
KR101991326B1 (ko) 2019-06-20
JP2020073570A (ja) 2020-05-14
ME02754B (me) 2018-01-20
IL228506A (en) 2016-11-30
EA201391332A1 (ru) 2014-04-30
US20160250199A1 (en) 2016-09-01
AU2012230761A1 (en) 2013-05-02
AU2017200745B2 (en) 2018-02-22
US20170326124A1 (en) 2017-11-16
DK2688403T3 (en) 2017-07-24
NZ713143A (en) 2017-05-26
IL243318B (en) 2020-02-27
KR20180100453A (ko) 2018-09-10
JP6649341B2 (ja) 2020-02-19
US9642842B2 (en) 2017-05-09
US10588898B2 (en) 2020-03-17
US11931350B2 (en) 2024-03-19
CN103702561A (zh) 2014-04-02
IL272165A (en) 2020-03-31
EP3290415A1 (en) 2018-03-07
IL272165B (en) 2021-07-29
PT3290415T (pt) 2021-03-29
US9044469B2 (en) 2015-06-02
PT2688403T (pt) 2017-07-13
CA2830742C (en) 2023-03-14
BR112013024136A2 (pt) 2020-01-14
PL3290415T3 (pl) 2021-07-19
US20150246904A1 (en) 2015-09-03
US20190343819A1 (en) 2019-11-14
SMT201700325T1 (it) 2017-09-07
US9309234B2 (en) 2016-04-12
IL228506A0 (en) 2013-12-31
JP6243949B2 (ja) 2017-12-06
EP2688403A1 (en) 2014-01-29
IL243318A0 (en) 2016-02-29
CA2830742A1 (en) 2012-09-27
JP2014508811A (ja) 2014-04-10
US8835488B2 (en) 2014-09-16
EP2688403B1 (en) 2017-05-31
JP2016155843A (ja) 2016-09-01
SI2688403T1 (sl) 2017-08-31
KR102129247B1 (ko) 2020-07-06
CY1119057T1 (el) 2018-01-10
US20220175747A1 (en) 2022-06-09
WO2012129495A1 (en) 2012-09-27
US11077098B2 (en) 2021-08-03
EP3872076A1 (en) 2021-09-01
KR20140047599A (ko) 2014-04-22
IL284407A (en) 2021-08-31
EP3290415B1 (en) 2020-12-30
AU2012230761B2 (en) 2016-11-03
HUE032948T2 (en) 2017-11-28
JP5912169B2 (ja) 2016-04-27
ES2632009T3 (es) 2017-09-07
JP2023075282A (ja) 2023-05-30
DK3290415T3 (da) 2021-03-22
PL2688403T3 (pl) 2017-09-29
HRP20171021T1 (hr) 2017-09-22
ES2857549T3 (es) 2021-09-29
HK1250984A1 (en) 2019-01-18
IL284407B (en) 2022-12-01
NZ615993A (en) 2015-11-27
JP2018048193A (ja) 2018-03-29
RS56111B1 (sr) 2017-10-31
US20130331408A1 (en) 2013-12-12
US20180311222A1 (en) 2018-11-01
EP2688403A4 (en) 2014-10-15
CN103702561B (zh) 2017-02-22
LT2688403T (lt) 2017-07-25
US9849119B2 (en) 2017-12-26
JP6923683B2 (ja) 2021-08-25
JP7248750B2 (ja) 2023-03-29
EA025456B1 (ru) 2016-12-30
IL284407B2 (en) 2023-04-01
JP2021176885A (ja) 2021-11-11
US20120245181A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
HUE054055T2 (hu) Opoid receptor ligandumok és eljárás azok alkalmazására és elõállítására
HUE052485T2 (hu) RNA készítmény immunterápiára
DK2661266T3 (da) Kemosensoriske receptorligandbaserede terapier
HUE036663T2 (hu) Készítmény anti-alfa4béta7 antitesthez
HUE036664T2 (hu) Készítmény anti-alfa4béta7 antitesthez
HUE044591T2 (hu) Anti-CD40 antitestek és alkalmazásuk
HUE036929T2 (hu) Alfa-folátreceptor elleni ellenanyagok és alkalmazásuk
HUE037048T2 (hu) Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására
DK3275892T3 (da) Præfusions-rsv-f-antigener
HRP20190576T1 (hr) Postupci pripreme konjugata
CO6890099A2 (es) Nuevos derivados dihidroquinolina-2-ona
BR112013033308A2 (pt) assento
EP2665707A4 (en) ANTAGONISTS OF THE MINERALOCORTICOID RECEPTOR
EP2752333A4 (en) SEAT DEVICE
IL229963A0 (en) Substituted quinolines and their use as medicaments
EP2665431C0 (en) Drug delivery technology
DK3246339T3 (da) Antistoffer mod bradykinin-b1-receptorligander
EP2785798C0 (en) ANTHOCYANIN-BASED DYE
EP2710925A4 (en) SEAT
GB201120991D0 (en) Microsensor
HUE052855T2 (hu) Kolonoszkópiás készítmény
BR112014015885A2 (pt) preparação farmacêutica
IL231660A0 (en) Composition
CO6960544A2 (es) Preparación de liberación sostenida
LT2742068T (lt) Nauji antikūnai prieš fosforilcholiną